Tidepool today announced a strategic collaboration with Oura to support a groundbreaking dataset for diabetes research. The initiative between the diabetes software developer and smart ring maker aims to create a comprehensive, multi-modal, … [Read More...] about Tidepool, Oura partner on data for diabetes research
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Billie Jean King supports Medtronic Diabetes awareness initiative
The annual Medtronic (NYSE:MDT) diabetes awareness initiative this year has the backing of sporting legend Billie Jean King. King, a former world No. 1 tennis player and pioneer in women's sports, is participating in the company's Blue Balloon … [Read More...] about Billie Jean King supports Medtronic Diabetes awareness initiative
Tandem stock rises after hours on Q3 beats, record sales
Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of TNDM rose nearly 20% to $15.89 apiece in post-market trading today. The San Diego-based … [Read More...] about Tandem stock rises after hours on Q3 beats, record sales
Insulet leadership talks patch pump competition, expanding type 2 diabetes market
As Insulet (Nasdaq:PODD) continues to grow in its leadership position within the insulin patch pump market, other entries could be on the way. The Acton, Massachusetts–based company's Omnipod platform has long been the leader in the patch pump … [Read More...] about Insulet leadership talks patch pump competition, expanding type 2 diabetes market
Insulet increases guidance again on Q3 beats, 30% sales uptick
Insulet (Nasdaq:PODD) shares rose slightly before hours today on third-quarter results that landed well ahead of the consensus forecast. Shares of PODD ticked up 2.4% to $322 apiece in pre-market trading today. The Acton, Massachusetts-based … [Read More...] about Insulet increases guidance again on Q3 beats, 30% sales uptick
Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year
Senseonics (NYSE:SENS) shares ticked up after hours today on third-quarter results that beat the consensus sales forecast. Shares of SENS rose 2.1% to $6.87 apiece in post-market trading today. The Germantown, Maryland-based long-term implantable … [Read More...] about Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year
MIT engineers develop drug delivery patch for post-heart attack healing
Engineers at MIT say they developed a flexible drug delivery patch for promoting healing and tissue regeneration after heart attacks. The patch, placed on the heart after a heart attack, can help both heal and regenerate cardiac tissue. MIT said … [Read More...] about MIT engineers develop drug delivery patch for post-heart attack healing
Tandem achieves cybersecurity certification milestone
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it achieved ISO/IEC 27001:2022 Certification from Insight Assurance. San Diego-based Tandem said the certification affirms its commitment to cybersecurity, data protection and operational … [Read More...] about Tandem achieves cybersecurity certification milestone
12 things you need to know about the CGM market
The CGM market is an exciting, fast-growing, multibillion-dollar sector for the medical device industry, according to our latest Medtech Market Intelligence Report for MassDevice. The report on the CGM market — available for purchase on MassDevice … [Read More...] about 12 things you need to know about the CGM market
Tidepool, Oura partner on data for diabetes research
Tidepool today announced a strategic collaboration with Oura to support a groundbreaking dataset for diabetes research. The initiative between the diabetes software developer and smart ring maker aims to create a comprehensive, multi-modal, … [Read More...] about Tidepool, Oura partner on data for diabetes research
Dexcom leadership addresses G7 issue claims, hopes for expanded CGM coverage
Amid some scrutiny over its latest-generation G7 continuous glucose monitor (CGM), Dexcom (Nasdaq:DXCM) officials addressed claims on the company's latest earnings call. A recent class action lawsuit brought G7 into the spotlight, demanding a jury … [Read More...] about Dexcom leadership addresses G7 issue claims, hopes for expanded CGM coverage
In case you missed it
- Modular Medical is seeking CE mark for its next-gen insulin pump
- CGM market report: Significant growth is ahead
- Dexcom stock is down after hours despite Q3 beats, raised sales guidance
- Insulet launches inclusion campaign for Diabetes Awareness Month
- Tidepool announces new permanent CEO appointment
- Tandem launches t:slim X2 pump with Abbott FreeStyle Libre 3 Plus
- Beta Bionics stock rises on Q3 beats, raised full-year guidance, advances iLet offerings
- Glucose monitor maker LifeScan is set to emerge from Ch. 11 bankruptcy
- Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement
- ViCentra adds Dexcom, Medtronic Diabetes veterans to leadership team
- Dexcom adds Stanford Medicine chair to its board of directors
- Boston Scientific shares positive Agent drug-coated balloon findings
- Vivani prices $15.7M offering
- Multiple studies back Cordis Selution SLR drug-eluting balloon
- Ypsomed launches YpsoLoop autoinjector platform designed for circularity
Clinical Trials
Tidepool, Oura partner on data for diabetes research
Tidepool today announced a strategic collaboration with Oura to support a groundbreaking dataset for diabetes research. The initiative between the diabetes software developer and smart ring maker aims to create a comprehensive, multi-modal, real-world dataset for diabetes, utilizing Tidepool’s diabetes device data paired with biometric data collected by the leading Oura Ring Gen 3. This […]
Boston Scientific shares positive Agent drug-coated balloon findings
Boston Scientific (NYSE: BSX) today shared findings from new analyses of its Agent drug-coated balloon (DCB). Agent serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent in-stent restenosis (ISR) reoccurrence. The FDA […]
Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial
Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion Balloon (SAB). The FDA investigational device exemption (IDE) trial compares the Virtue SAB to the Boston Scientific Agent paclitaxel-coated balloon. Agent is currently the only FDA-approved drug-coated balloon (DCB) for coronary indication, picking up approval in March. New Hope, […]
Multiple studies back Cordis Selution SLR drug-eluting balloon
Cordis today announced new findings from a duo of studies supporting the use of its Selution SLR drug-eluting balloon (DEB) system. Miami Lakes, Florida-based Cordis announced results from the SELUTION DeNovo and SELUTION 4ISR trials at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Both randomized clinical trials demonstrated positive outcomes that met […]
SiBionics reports strong CGM, ketone monitoring data
SiBionics announced the presentation of new data supporting its continuous glucose monitoring (CGM) and ketone monitoring (CKM) devices. The China-based company shared findings for its integrated CGM and CKM diabetes management solution as well. It showcased the technology at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria. […]
